Monitoring of plasmin and plasminogen activator activity in blood of patients under fibrinolytic treatment by reteplase

Clinical and Applied Thrombosis/Hemostasis

Volumn 12, Issue 2, 2006, Pages 213-218

  Stief, T W ^a   Richter, A ^a   Bunder R ^a   Maisch, B ^a   Renz, H ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

Laboratory medicine; Plasmin; Plasminogen activator; Thrombolysis

Indexed keywords

ARGININE; EDETIC ACID; OXYGEN; PLASMIN; PLASMINOGEN ACTIVATOR; RETEPLASE; TISSUE PLASMINOGEN ACTIVATOR; FIBRINOLYTIC AGENT; RECOMBINANT PROTEIN;

ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG INFUSION; ENZYME ACTIVITY; ENZYME ASSAY; FIBRINOLYTIC THERAPY; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; TREATMENT DURATION; BLOOD; CLINICAL TRIAL; KINETICS; METHODOLOGY;

ARGININE; BLOOD SPECIMEN COLLECTION; FIBRINOLYTIC AGENTS; HUMANS; KINETICS; MYOCARDIAL INFARCTION; PLASMIN; PLASMINOGEN ACTIVATORS; RECOMBINANT PROTEINS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 33747754445     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960601200210     Document Type: Article

References (28)

1. Murray CL, Lopez AD. Mortality by cause for eight regions of the world: Global burden of disease study. Lancet 1997;349:1269.
2. Collen D, Lijnen HR. The fibrinolytic system in man. Crit Rev Hematol Oncol 1986;4:249.
3. Bick RL, Murano G. Physiology of thrombosis. Clin Lab Med 1994;14:677.
4. Stief TW, Hinz F, Kurz J, et al. A simple functional screening assay for fibrinolysis parameters (FIPA). Thromb Res 2000;97:231.
5. Dunn CJ, Goa KL. Tenecteplase: A review of its pharmacology and therapeutic efficacy in patients with acute myocardial infarction. Am J Cardiovasc Drugs 2001;1:51.
6. Nordt TK, Bode C. Thrombolysis: Newer thrombolytic agents and their roles in clinical medicine. Heart 2003;89:1358.
7. Khan IA, Gowda RM. Clinical perspectives and therapeutics of thrombolysis. Int J Cardiol 2003;91:115.
8. Baker WF Jr. Thrombolytic therapy: Clinical applications. Hematol Oncol Clin North Am 2003;17:283.
9. Bell WR. Present-day thrombolytic therapy: Therapeutic agents - pharmacokinetics and pharmacodynamics. Rev Cardiovasc Med 2002;3(suppl 2):S34.
10. Chen M, Arjomand H, Pollack CV Jr. The evolution of thrombolytic therapy and adjunctive antithrombotic regimens in acute ST-segment elevation myocardial infarction. Am J Emerg Med 2004;22:14.
11. Warlow C. Stroke: Killer clots and killer drugs. J Thromb Haemost 2003;1:1422.
12. Stief TW, Richter A, Bünder R, et al. Functional determination of plasmin in arginine-stabilized plasma. Clin Appl Thromb Hemost 2005;11:303.
13. Stief TW, Richter A, Bünder R, et al. Functional determination of plasminogen-activator in arginine-stabilized plasma. Clin Appl Thromb Hemost 2005;11:311.
14. Verstraete M, Bounameaux H, de Cock F, et al. Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue type plasminogen activator (rt-PA) in humans. J Pharmacol Exp Ther 1985;235:506.
15. Lijnen HR, Uytterhoeven M, Collen D. Inhibition of trypsin-like serine proteinases by tripeptide arginyl and lysyl chloromethyl ketones. Thromb Res 1984;34:431.
16. Mohler MA, Refino CJ, Chen SA, et al. D-Phe-Pro-Arg-chloromethylketone: Its potential use in inhibiting the formation of in vitro artefacts in blood collected during tissue-type plasminogen activator thrombolytic therapy. Thromb Haemost 1986;56:160.
17. 2Cl and aprotinin for prevention of in vitro effects of recombinant tissue-type plasminogen activator on haemostasis parameters. Thromb Haemost 1987;58:921.
18. Stief TW, Weippert M, Kretschmer V, Renz H. Arginine inhibits hemostasis activation. Thromb Res 2001;104:265.
19. Seifried E, Müller M, Martin U, et al. Bolus application of a novel recombinant plasminogen activator in acute myocardial infarction patients: Pharmacokinetics and effects on the hemostatic system. Ann NY Acad Sci 1992;667:417.
20. Stief TW, Stief MH, Ehrenthal W, et al. Nonradical oxidants of the phagocyte type induce the activation of plasmatic single-chain urokinase. Thromb Res 1991;64:597.
21. Stief TW, Bünder R, Richter A, et al. In vitro simulation of therapeutic plasmatic thrombolysis. Clin Appl Thromb Hemost 2003;9:211.
22. Moroz LA. Increased blood fibrinolytic activity after aspirin ingestion. N Engl J Med 1977;296:525.
23. 2/hv). Clin Appl Thromb Hemost 2000;6:22.
24. Stief TW. The blood fibrinolysis/deep-sea analogy: A hypothesis on the cell signals singlet oxygen/photons as natural antithrombotics. Thromb Res 2000;99:1.
25. Sigal A, Bleijs DA, Grabovsky V, et al. The LFA-1 integrin supports rolling adhesions on ICAM-1 under physiological shear flow in a permissive cellular environment. J Immunol 2000;165:442.
26. Entman ML, Youker K, Shappell SB, et al. Neutrophil adherence to isolated adult canine myocytes. Evidence for a CD18-dependent mechanism. J Clin Invest 1990;85:1497.
27. Shapell SB, Toman C, Anderson DC, et al. Adherence-dependent neutrophil hydrogen peroxide secrection is mediated by Mac-1 (CD11/18). J Immunol 1989;144:2702.
28. Grether-Beck S, Olaizola-Horn S, Schmitt H, et al. Activation of transcription factor AP-2 mediates UVA radiation- and singlet oxygen-induced expression of the human intercellular adhesion molecule 1 gene. Proc Natl Acad Sci USA 1996;93:14586.